Novo CFO on guidance upgrade: Mainly due to tax rebates
Novo Nordisk reports significant growth in the first quarter, but a large part of the sales increase – approximately 5% – can be attributed to the phasing of rebates in 2023.
by MARKETWIRE
Novo Nordisk delivered massive double-digit growth in the first quarter, but a good part of the sales increase – around 5% – is due to rebates related to previous years, Novo Nordisk CFO Karsten Munk Knudsen, said on a press teleconference on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk upgrades 2024 guidance
For subscribers
